Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EKF Molecular Launches Cancer Gene Detection Technologies at ASCO

Published: Monday, May 27, 2013
Last Updated: Monday, May 27, 2013
Bookmark and Share
PointMan™ DNA Enrichment kits to be introduced at ASCO 2013 Stand 19117.

EKF Diagnostics has announced the launch of EKF Molecular Diagnostics’ PointMan™ DNA Enrichment kits at ASCO 2013, 31st May - 4th June, Chicago.

The global launch will comprise three kits for enriching mutations in BRAF, KRAS and EGFR T790M genes associated with skin melanoma, colorectal and lung cancers.

PointMan kits offer highly-specific and ultra-sensitive enrichment of mutant genes in a background of wild-type (normal) genes that is unmatched by existing technologies.

The launch of the new PointMan kits on Stand 19117 is the first new product introduction since EKF’s acquisition of 360 Genomics Limited and the establishment of EKF Molecular Diagnostics in March 2013.

EKF Molecular was set up to offer innovative products with the potential to change current DNA extraction and detection practices, in order to best support the fast growing companion diagnostics market.

PointMan, is a real-time PCR technology that provides reliable and extremely sensitive detection for cancer mutations.

It is highly efficient in amplifying the target sequence of interest, whilst suppressing amplification of the wild-type.

The resulting sample is effectively enriched for the mutation, thereby having the potential to offer industry leading sensitivity in a wide variety of sample types.

PointMan DNA enrichment kits can also be used to enrich all mutant sequences within the gene of interest using a single set of reagents, unlike competing technology that requires a separate reagent set for each mutation within a gene sequence.

These kits offer fast, efficient and cost effective enrichment of mutant gene sequences for researchers in the pharmaceutical industry developing anti-cancer therapies.

At ASCO, EKF Molecular Diagnostics will also premiere its pipeline of PointMan enrichment kits currently in development for other cancer-related mutations.

The three PointMan kits initially being launched for the Research Use Only market, with planned diagnostic registration in Europe in 2014, are:
PointMan BRAF DNA Enrichment Kit
The BRAF gene has proven utility in the treatment of melanoma, as well as colorectal cancer.
PointMan KRAS DNA Enrichment Kit
The KRAS gene has proven utility in the treatment of colorectal cancer.
PointMan EGFR T790M DNA Enrichment Kit
T790M mutation in EGFR (epidermal growth factor receptor) has been associated with about 50% of patients who develop resistance to EGFR targeted therapies in non-small cell lung cancer.

Andrew Webb, Chief Executive Officer of EKF Molecular, said: “The launch of these three kits, which are the first in a line of further expected PointMan product launches, comes ahead of schedule and represents step one in our operational development plan for the newly established EKF Molecular Diagnostics.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PointMan™ Enriches Low-level DNA Mutations from Whole Blood
Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment.
Wednesday, January 22, 2014
Scientific News
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Lose Weight, Escape the Eight: Weight-Based Cancer Risk
IARC has identified eight additional cancer sites linked to overweight and obesity.
Coffee Consumption Linked to Genes
Researchers have identified a gene that influences coffee consumption. The gene is thought to relate to caffeine breakdown.
Emerging Model of Cancer
Cancer acts cooperatively, making individual decisions but acting in unison; this insight is being used to create a computer model of cancer.
Biological Barcodes Using CRISPR
Using genome editing tools, researchers are getting closer to understand differentiation of various cell types during development.
Controlling DNA Repair
Scientists discover that DNA repair outcomes following CRISPR-Cas9 cleaving are non-random and can be harnessed to produce desired effects.
Demonstrating LNP Delivery of CRISPR Components
Intellia has presented data demonstrating in vivo gene editing ising liquid nanoparticles (LNPs) to deliver CRISPR/Cas9.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Creating Embryos with 'Heteroplasmy'
New discovery in genetic research could lead to treatments for mitochondrial diseases.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!